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Abstract DNA repair is an important factor of stability of pro-
and eukaryotic genomes which plays a central role in mutagen-
esis and carcinogenesis. Genetic control of nucleotide excision
repair (NER) in mammalian cells is well studied, but little is
known about molecular mechanisms of postreplication repair
(PRR) which allows bypass of base lesions in template strands
after DNA replication. In Saccharomyces cerevisiae PRR is
controlled by the RAD6/RAD18 pathway which involves POL30
gene encoding proliferating cell nuclear antigen (PCNA), and in
human cells PCNA is known to be closely associated with the
newly replicated chromatin where PRR probably takes place. In
UV-irradiated human cells distinct PCNA foci may be detected
in some cells which accumulate phosphorylated breast cancer
susceptibility protein BRCA1 and another protein BARD1.
Human PCNA is also known to be phosphorylated after UV-
irradiation. In this study we found that the known inhibitor of
protein kinases staurosporine supresses PRR in NER-deficient
cells which is consistent with the view that BRCA1 and PCNA
are required for PRR. We also have shown that the distinct
PCNA foci in UV-irradiated NER-deficient cells are actually
associated with the newly replicated chromatin. Since RAD18
protein is not essential for normal DNA replication and directly
controls PRR in yeast, we analysed whether this protein as well
as its human homologs (HR18A and HR18B) have common
domains with BRCA1 and BARD1. It is found that HR18A has a
subregion of homology to BARD1 and HR18A-to BRCA1.
Taken together the results indicate that BRCA1 and BARD1
may be involved in PRR in human cells.
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1. Introduction
Ultraviolet (UV) irradiation of living cells introduces stable
chemical lesions into DNA which interfere with its functions
and, for cell survival, should be either eliminated or tolerated
(bypassed). One well studied mechanism of elimination of the
lesions from mammalian genomes is nucleotide excision repair
(NER) involving nucleolytic excision of damaged DNA seg-
ments followed by local resynthesis performed by speci¢c mul-
tiprotein complexes before DNA replication [1,2]. Genetic
control of NER is well studied and several human diseases
are identi¢ed caused by mutations in NER genes, e.g. xero-
derma pigmentosum (XP) or Cockayne syndrome [1]. How-
ever, some unexcised lesions may enter S-phase, and normal
replication machinery cannot copy damaged DNA leaving
single-strand gaps in daughter strands opposite the lesions
which are then slowly repaired without elimination of the
lesions from template strands [3,4]. This process of ¢lling of
the daughter-strand gaps (DSG) opposite the lesions in the
newly replicated chromatin and called postreplication repair
(PRR) is thought to be the main source of the DNA damage-
induced mutations but, surprisingly, no gene was identi¢ed so
far controlling PRR in mammalian cells. In Saccharomyces
cerevisiae PRR is controlled by the RAD6/RAD18 pathway
which involves proliferating cell nuclear antigen (PCNA)
and DNA polymerase N [5^7]. Two mammalian homologs
of the yeast RAD6 gene (HR6A and HR6B) were identi¢ed
and inactivation of one them (HR6B) in mice was shown to
lead to male sterility but no defect of PRR was found [8].
Double HR6A/HR6B knockout mice or stem cells were not
isolated indicating that activity of at least one of the genes is
essential for cell viability. Some xeroderma pigmentosum (XP)
cells (XP variant) show defects in PRR [9,10] but an under-
lying genetic defect is not yet known.
PRR is taking place in the newly replicated chromatin dur-
ing 2^3 h following formation of DSG in S-phase human cells
[9,10]. Replication foci in normally proliferating mammalian
cells are known to contain tightly bound DNA polymerase N
accessory factor PCNA [11^13]. As was shown earlier [14]
replication foci co-localize with chromatin assembly factor 1
(CAF-1) and, therefore, mark the newly replicated chromatin.
In UV-irradiated human cells PCNA is known to be phos-
phorylated and the phosphorylation is inhibited by stauro-
sporine [15]. It has also been shown recently [16] that in
UV-irradiated NER-pro¢cient human cells the major breast
cancer susceptibility protein BRCA1 also becomes phospho-
rylated and relocates to the nuclear foci containing PCNA.
Human homologs of the yeast RAD51 and protein BARD1
show similar behavior and the results indicate that BRCA1/
RAD51/BARD1 may be directly involved in DNA repair
functioning as ‘caretaker’ of the genome integrity [17]. It
was suggested [16] that after UV-irradiation phosphorylated
BRCA1 mainly relocates to the newly replicated chromatin of
S-phase cells, but in the NER-pro¢cient cells used in this
study [16] PCNA foci may also be associated with non-S-
phase NER sites [18], or with non-NER non-S-phase sites
accumulating p21 (Cip1, WAF-1) protein [19].
In this study we have shown that the repair of DSG in
completely NER-de¢cient cells may be inhibited by stauro-
sporine and that distinct PCNA foci in UV-irradiated NER-
de¢cient cells are actually associated with the newly replicated
chromatin. BARD1 and BRCA1 proteins are also shown to
FEBS 20243 25-5-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 4 7 7 - 3
*Corresponding author. Fax: (7) (812) 2470341.
E-mail: nvtom@link.cytspb.rssi.ru
FEBS 20243 FEBS Letters 428 (1998) 23^26
contain regions of statistically signi¢cant homology to human
homologs of the yeast RAD18 protein HR18A and HR18B,
respectively. Taken together, the results suggest that BRCA1
and BARD1 may be directly involved in PRR in human cells.
2. Materials and methods
2.1. Nuclear foci in NER-de¢cient human cells
The cells (xeroderma pigmentosum complementation group A
XP25RO primary ¢broblasts) were grown in Dulbecco’s modi¢ed
Eagle medium (DMEM) containing 5% fetal bovine serum on micro-
scopic glass slides in Petri dishes. Two hours before UV-irradiation
5-£uorodeoxyuridine was added to 0.01 mM ¢nal concentration.
After washing with phosphate-bu¡ered saline (PBS) cells were UV-
irradiated (254 nm, 30 J/m2) and incubated for 1 h in the growth
medium containing 0.01 mM 5-iododeoxyuridine (IdU). After wash-
ing with PBS, the slides were treated for 2 min at room temperature
(RT) with 0.1% Triton X-100 in PBS, washed again with PBS, ¢xed
for 10 min in ice-cold 4% formaldehyde solution in PBS, kept in 80%
ethanol at 4‡C overnight, dehydrated in ethanol and dried. After
incubation in PBS for 15 min at RT, slides were again treated with
Triton X-100 (0.1% solution in PBS, 2 min at RT), washed two times
with PBS, incubated in 1% blocking reagent (Boehringer) in PBS with
0.02% Tween 20 for 15 min at 37‡C and rinsed with 0.5% blocking
reagent with 0.02% Tween 20. All dilutions of antibodies and washes
were in the same solution and incubations were at 37‡C. Then slides
were sequentially treated with mouse monoclonal anti-PCNA anti-
bodies (1:30, Oncor), 1 h; biotinylated sheep-anti-mouse IgG
(1:100, Sigma), 40 min; avidin-Texas Red (1:50, Vector), 40 min;
goat-anti-mouse non-tagged IgG (1:20, Sigma), 1.5 h (to block the
mouse epitopes); 4 N HCl, 30 min at RT; monoclonal mouse anti-
bodies against 5-bromodeoxydine which react with IdU (clone iso-
lated by Dr. M. Filatov, 1:50), 60 min; rabbit-anti-mouse IgG
(1:50, Sigma), 40 min; and FITC-tagged goat-anti-rabbit IgG
(1:100, Miles), 40 min. Then slides were mounted in antifade solution
(50 mg/ml propylgallate in glycerol). Conventional £uorescent micros-
copy was done using an Opton ICM-405 inverted epi£uorescence
microscope equipped with appropriate objective and ¢lters.
2.2. Analysis of postreplication DNA repair
The cells (SV40-transformed XP12RO cell line) were grown as in
Fig. 1. XP12RO cells contain the same mutations in the XPA gene as
XP25RO cells. After washing in PBS and UV-irradiation (5 J/m2, 254
nm) cells were incubated for 30 min at 37‡C in the growth medium
with 5% serum containing [3H]thymidine (20 WCi/ml, 16 Ci/mmol),
and then for 3 h in non-radioactive DMEM with 10% serum. Stau-
rosporine (200 nM) was added to growth medium 30 min before UV-
irradiation and was also present in the medium during subsequent
incubations. The cells were then washed in cold isotonic EDTA, col-
lected using a rubber policeman and placed (105 cells in 0.1 ml) on the
top of an alkaline sucrose gradient (5^30% in 0.9 M NaCl, 0.3 M
NaOH, 10 mM EDTA) overlayed with 0.1 ml of the lysis bu¡er (0.6
M NaOH, 0.2 M NaCl, 1% sarcosyl, 20 mM EDTA, 0.5 Wg/ml pro-
teinase K). The gradients were centrifuged at 30 000 rpm for 90 min at
20‡C in an SW-50.1 rotor of an L2-65K Beckman ultracentrifuge.
Fractions were then collected on ¢lter paper discs which were washed
in cold 5% trichloroacetic acid, ethanol and radioactivity was meas-
ured in a liquid scintillation counter.
3. Results and discussion
Fig. 1 shows sedimentation pro¢les in alkaline sucrose gra-
dients of the newly synthesized DNA in NER-de¢cient cells
treated or not treated with staurosporine. After 30 min label-
ing with [3H]thymidine of the non-irradiated or UV-irradiated
cells they were incubated for 3 h in growth medium, then
lysed and sedimented. Control non-irradiated cells show
only fastly sedimenting DNA independently of the presence
of staurosporine but after UV-irradiation staurosporine was
found to inhibit repair of daughter-strand gaps. Total number
of the acid-insoluble counts was about the same in all variants
(see legend to Fig. 1) indicating that UV-irradiation did not
repress DNA synthesis and the drug did not induce DNA
degradation (apoptosis) under our experimental conditions.
Since staurosporine inhibits most protein kinases by mimick-
ing several aspects of adenosine binding [20], our results sug-
gest that phosphorylation of a repair protein is required for
PDR in NER-de¢cient human cells.
At least three relevant proteins are known to be phospho-
rylated in UV-damaged cells ^ PCNA [15], p34 subunit of
replication factor A (p34-RPA) [21] and BRCA1 [16]. Hyper-
phosphorylation of p34-RPA correlates with UV-induced
loss of activity of the DNA replication complex and was sug-
gested to play a role in DNA synthesis arrest [21] but a pos-
sible role of this protein in PRR is not established. PCNA is
known to be involved in PRR in Saccharomyces cerevisiae
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Fig. 1. Inhibition of postreplication DNA repair in XP12RO cells
(SV40-transformed cell line) by staurosporine. For experimental de-
tails see Section 2. Total tritium counts recovered from gradients
were: 71 000 (plus), 56 000 (small squares), 99 600 (stars) and 84 400
(big squares). SE, staurosporine; UV, UV-irradiation, 254 nm,
5 J/m2.
Fig. 2. Two types of nuclear foci containing tightly-bound PCNA in
UV-irradiated NER-de¢cient cells. Two UV-irradiated (30 J/m2, 254
nm) XP25RO cells (primary ¢broblasts) doubly labeled for Triton-
unextractable PCNA (left) and incorporated 5P-iododeoxyuridine
(IdU) are shown. S-phase cells (S, top) incorporate large amounts
of IdU into big replication foci, and non-S-phase cells (S3, bottom)
do not incorporate IdU at all.
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[5,6] and in non-irradiated mammalian cells p34-RPA and
PCNA co-localizes in nuclei with newly replicated chromatin
[11^14,22] but the relation of the proteins to newly replicated
chromatin in UV-irradiated cells is unknown. In non-irradi-
ated S-phase and G2 cells BRCA1 is located in distinct nu-
clear foci which do not coincide during S-phase with newly
replicated chromatin and PCNA [16]. After UV-irradiation of
NER-pro¢cient cells BRCA1 translocates to nuclear foci also
containing PCNA and it was suggested that the foci represent
newly replicated chromatin [16]. However, in UV-irradiated
NER-pro¢cient cells PCNA foci may also be associated with
non-S-phase NER sites [18] as well as with non-NER non-S-
phase sites containing p21 (WAF1/Cip1) [19]. Therefore, it
remained unclear whether in UV-irradiated cells phosphoryl-
ated BRCA1 actually associates with newly replicated chro-
matin.
We studied this question by simultaneous double labeling of
the UV-irradiated NER-de¢cient cells for newly replicated
chromatin (incorporated 5-iododeoxyuridine, IdU) and
PCNA. The results presented in Fig. 2 indicate that after
UV-irradiation of XP25RO cultures two subpopulations of
cells containing tightly bound PCNA may be seen: one rep-
resents S-phase cells incorporating IdU with big distinct foci
(Fig. 2, top), and the other non-S-phase cells showing more
dispersed and uniform PCNA staining (Fig. 2, bottom). This
result suggests that after UV-irradiation tightly bound PCNA
does not disappear from big foci of newly replicated chroma-
tin of S-phase cells. Since similar big and distinct PCNA foci
accumulating BRCA1 protein were observed in UV-irradiated
cells [16] we believe that phosphorylated BRCA1 actually
translocates to newly replicated chromatin as was suggested
earlier [16]. Dispersed PCNA staining in non-S-phase cells
may be indicative of base excision repair of minor UV lesions
[19] which requires PCNA [23].
It is likely that in UV-irradiated S-phase human cells tight
association of PCNA with newly replicated chromatin re£ects
direct involvement of this protein in PDR. This protein may
be involved in the translesion DNA synthesis in daughter-
strand gaps [4,24] stabilized by a mammalian analog of the
yeast RAD6/RAD18 complex [7], and co-localization of
PCNA with BRCA1 in UV-irradiated S-phase cells [16] may
be indicative of possible involvement of BRCA1 in PRR. The
UV-induced PCNA/BRCA1 positive foci also accumulate [16]
BRCA1-associated RING domain protein, BARD1 [25]. Both
BRCA1 and BARD1 contain conserved C-terminal domain
(BRCT) which is thought to be involved in DNA damage-
responsive checkpoints [26] but the domain is also present in
some DNA repair proteins including yeast REV1 protein
[26,27] which requires deoxycytidyl transferase for mutagenic
bypass of abasic sites in template DNA [28]. REV1 gene is a
member of the RAD6 epistasis group controlling PRR after
UV-irradiation of yeast cells [5^7]. Yeast RAD18 protein [7]
which is not involved in DNA damage checkpoints in yeast
[29] as well as mammalian BRCA1 and BARD1 proteins [25]
are known to contain N-terminal RING domain (C3HC4)
which may be responsible for DNA-binding activity of the
proteins. In this study we examined whether the two human
homologs of yeast RAD18 protein present in dbEST database
(HR18A and HR18B, accession numbers AA311754 and
AA313966, respectively) are homologous to BRCA1 and
BARD1. We found that HR18A is statistically signi¢cant ho-
mologous to the RING ¢nger region of BARD1 (Fig. 3A)
and HR18B is homologous to a similar region of BRCA1
(Fig. 3B) indicating that the two proteins may have common
origin and function. Similarity of DNA-binding RING do-
mains of BRCA1, RAD18 and HR18B proteins is consistent
with the view that the targeting of phosphorylated BRCA1 to
the newly replicated chromatin in UV-irradiated cells [16] may
be driven by the a⁄nity of its RING domain to the long-
living daughter-strand gaps opposite UV-lesions. In this con-
nection it may be noted that de¢ciency in DNA repair is
detected in some human familial breast cancer cells [30] but
it remains to be established whether the cells have mutations
in the BRCA1 gene.
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